2022年第64届美国放射肿瘤学会年会(ASTRO)

Important Deadlines-重要截止日期

1. Abstracts must be received by 11:59 p.m. Pacific time, Tuesday, March 1, 2022. Abstracts may be edited up until the deadline. Abstracts will be considered ineligible for review if they are incomplete. Abstracts that are unpaid or have payment issues will not be considered. If you do not receive a confirmation receipt, follow up with ASTRO to confirm your “complete” status.
2. Revisions: Please proof your abstract carefully for formatting, spelling and data errors. Pay special attention to the author order and presenting author designation. Review your confirmation email, as this is how the abstract will be published. Errors can be corrected if sent to ASTRO by June 30, 2022. After this date, we cannot make any corrections. This rule is strictly enforced. Please note: revisions should not be substantive, and should not alter the results or the conclusions of the abstract. Revisions are meant only to correct errors that were made in the initial submission.
3. Notifications: The person listed as Presenting Author will be notified via email of the disposition of the abstract by late-May 2022. Abstract acceptance obligates the author to present the paper and pay the meeting registration fee. If circumstances prevent attendance, you must notify ASTRO and arrange for an alternate presenter, preferably a co-author.
4. Withdrawals: If you choose to withdraw your abstract, please change your decision to “withdraw” in the Speaker Center by June 30, 2022 and notify ASTRO staff via email. After this date, your abstract will be published exactly as it was submitted in the International Journal of Radiation Oncology • Biology • Physics (Red Journal).
5. Late-breaking Abstracts: The late-breaking abstract submission site will open on July 25, 2022, and close August 10, 2022.
6. Submission of an abstract conveys permission to be posted online and printed in the International Journal of Radiation Oncology • Biology • Physics (Red Journal) (www.redjournal.org).

Presenting Author Responsibility-展示作者的责任

1. An individual may submit more than one abstract in which they are indicated as the presenting author. However, they may only present one oral presentation. If more than one abstract is selected for oral presentation, an alternate presenter must be assigned, preferably a co-author (this does not apply to poster presentations).
2. It is the submitter’s responsibility to ensure up-to-date and accurate disclosures are submitted for each co-author on the abstract. ASTRO manages and reports all disclosures as submitted. Potential conflicts with commercial interest for the presenting author and all co-authors must be disclosed at the time of submission.
3. The presenting author will receive all notifications and email communications related to the accepted abstract(s). The presenting author is responsible for informing all co-authors of acceptance to ASTRO’s Annual Meeting.
4. ASTRO has developed a policy to handle any violations to the ASTRO Disclosure policy. Any reported violations will be researched and handled according to policy, which can include removal from presenting at future conferences.
5. Obligation to Register: Acceptance of an abstract obligates the author to present the paper and pay the meeting registration fee. If circumstances prevent attendance, you must notify ASTRO and arrange for an alternate presenter, preferably a co-author. If the presenting author does not register and attend the meeting, your abstract will be removed from the program.

Presentation at Other Meetings

1. Abstracts should contain new material that has not been presented or published prior to the ASTRO Annual Meeting, October 23-26, 2022. Previously presented abstracts will not be eligible for ASTRO’s official Press Program or Plenary Session.
2. If the same abstract is accepted for presentation at another major medical meeting or accepted for publication after March 1, 2022, the presenting author must notify ASTRO. The Scientific Committee will review and decide on a case-by-case basis if the abstract will remain in the program.

Properly Formatted Abstract

1. Abstracts must be properly formatted and organized into four sections identified by the following bolded headers: Purpose/Objectives, Materials/Methods, Results and Conclusions.
2. Abstracts should include a scientific hypothesis in the Purpose/Objectives section, and implications for research, policy or practice in the Conclusions section, when applicable.
3. Presentations must give a balanced view of therapeutic options. Brand names of pharmaceuticals and trade names of medical devices cannot be used in the title or body of the abstract. ASTRO reserves the right to replace proprietary names with generic names.
4. Institution names should not be included in the title or body of the abstract. Alternative language is “at one institution” or “a multi-institution” study, etc. This does not apply to cooperative research group names. 
5. The abstract title should not include results. 
6. The abstract cannot contain illustrations, images or graphs. If the abstract is accepted, presenters may include these items in their on-site presentations.
7. An abstract may contain one small table. The maximum character limit, including the title and body of the abstract, is 2,600 characters. Spaces are not counted.
8. A maximum of 20 authors’ names may be listed on each abstract. There are no exceptions. Authorship credit should only be given if all three of the following criteria are met. There is not mechanism for listing co-lead authors, or co-PI’s. Each author must have made substantial contributions to:
   • conception and design, or analysis and interpretation of data, and
   • drafting the abstract or revising it critically for important intellectual content, and
   • final approval of the version to be submitted/published.

Late-breaking Abstracts